Spring til indhold.
Forside

Auditorium A

The Department of Clinical Medicine

PhD defense by Lars Hernández Nielsen

The Department of Clinical Medicine, Aalborg University and Aalborg University Hospital are pleased to invite to PhD defense by Lars Hernández Nielsen who will defend the thesis entitled: Individual-based Registrations Of Systemic Anti-cancer Therapy For Monitoring Expenditures And Access To Treatment

Auditorium A

Forskningens Hus,
Aalborg Universitetshospital

  • 01.11.2024 Kl. 13:00 - 17:00

  • After the defense there will be held a reception. All are welcome.

  • English

  • On location

Auditorium A

Forskningens Hus,
Aalborg Universitetshospital

01.11.2024 Kl. 13:00 - 17:00

English

On location

The Department of Clinical Medicine

PhD defense by Lars Hernández Nielsen

The Department of Clinical Medicine, Aalborg University and Aalborg University Hospital are pleased to invite to PhD defense by Lars Hernández Nielsen who will defend the thesis entitled: Individual-based Registrations Of Systemic Anti-cancer Therapy For Monitoring Expenditures And Access To Treatment

Auditorium A

Forskningens Hus,
Aalborg Universitetshospital

  • 01.11.2024 Kl. 13:00 - 17:00

  • After the defense there will be held a reception. All are welcome.

  • English

  • On location

Auditorium A

Forskningens Hus,
Aalborg Universitetshospital

01.11.2024 Kl. 13:00 - 17:00

English

On location

About the PhD thesis

The purpose of this PhD project was to investigate the possibilities of
using patient-level data to analyze the use of systemic anti-cancer
therapy (SACT). The thesis consists of four scientific studies. Three of
the studies are based on SACT administered at Aalborg University
Hospital from 2008 to 2021 and one is based on data from disease
specific databases. In addition, one study uses English SACT data to
compare across countries. The main findings from each study are
summarized below:

Study I. The cost of SACT is concentrated on a small group of highcost patients spread across a range of cancer diagnoses. We found that increasing costs were partly driven by increased treatment of older patients and that the patients BMI is an increasingly important determinant of cost.

Study II. For patients with aggressive hematological malignancies (MM, AML, DLBCL), we found a reduced inequality in survival across socioeconomic position over the past 20 years, except for AML where the difference is still substantial. This difference could not be attributed to differences in treatment.

Study III. The socioeconomic position of cancer patients influences the initiation, type, and amount of SACT. Differences were found across length of education, income, cohabitation status, and to a lesser extent for the distance to treatment and ethnicity.

Study IV. Vulnerable cancer patients have a lower rate of participation
in clinical cancer trials in Denmark and in England. In comparing participation across countries, we found similar patterns in different cancers.

The studies underscore the potential in leveraging patient-level data to investigate patterns in use and distribution of SACT.

Attendees

in the defence
Supervisors
  • Associate Professor, Rasmus Froberg Brøndum, Center for Clinical Data Science, Aalborg University and Aalborg University Hospital
  • Professor, Martin Bøgsted, Center for Clinical Data Science, Aalborg University and Aalborg University Hospital
  • Clinical Professor, Marianne Tang Severinsen, Department of Hematology, Aalborg University Hospital, Department of Clinical Medicine, Aalborg University
Assessment committee
  • Professor, Jan Sørensen (chair), Royal College of Surgeons in Ireland, Department of Clinical Medicine, Aalborg University
  • Professor, Bernard Rachet, London School of Hygiene & Tropical Medicine
  • Professor, Mette Nørgaard, Department of Clinical Medicine, Aarhus University

Contact